title: Neuroinfections and antimicrobials: do we need new molecules or new strategies?
abstract: Within last 15 years, analyzing patterns of etiology and resistance in organisms causing neuroinfections, emergence of resistance has been observed in Slovakia in S. haemolyticus to teicoplanin (11%), Ps. aeruginosa and A. baumannii to meropenem (20%) and Candida spp. (non-albicans Candida spp.) to fluconazol (20%). There are no new antibiotics against carbapenem resistant Ps. aeruginosa and Acinetobacter baumannii.
authors.affiliation: St. Elisabeth University, College of Health and Social Sciences, Bratislava, Slovakia.
authors.forename: E
authors.initials: E
authors.lastname: Kalavsky
authors.forename: P
authors.initials: P
authors.lastname: Kisac
authors.forename: M
authors.initials: M
authors.lastname: Huttova
authors.forename: J
authors.initials: J
authors.lastname: Benca
authors.forename: V
authors.initials: V
authors.lastname: Krcmery
mesh_terms: D000890:Anti-Infective Agents / Q000627:therapeutic use*; D001927:Brain Diseases / Q000188:drug therapy / Q000382:microbiology; D002177:Candidiasis / Q000188:drug therapy; D003428:Cross Infection / Q000188:drug therapy* / Q000382:microbiology; D004352:Drug Resistance, Microbial; D015725:Fluconazole / Q000627:therapeutic use; D006801:Humans; D008581:Meningitis / Q000188:drug therapy* / Q000382:microbiology; D000077731:Meropenem; D011552:Pseudomonas Infections / Q000188:drug therapy; D013203:Staphylococcal Infections / Q000188:drug therapy; D017334:Teicoplanin / Q000627:therapeutic use; D013845:Thienamycins / Q000627:therapeutic use
chemical_list: D000890:Anti-Infective Agents; D013845:Thienamycins; D017334:Teicoplanin; D015725:Fluconazole; D000077731:Meropenem